Flare phenomenon in positron emission tomography in a case of breast cancer-a pitfall of positron emission tomography imaging interpretation

Clinical Imaging

Volumn 33, Issue 6, 2009, Pages 468-470

  Tu, Dom Gene ^a,c   Yao, Wei Jen ^b   Chang, Tsai Wang ^b   Chiu, Nan Tsing ^b   Chen, Yi Hsun ^a  

^a CHIA YI CHRISTIAN HOSPITAL   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^c CHANG JUNG CHRISTIAN UNIVERSITY   (Taiwan)

Author keywords

Breast cancer; F 18 FDG PET CT; Flare phenomenon; Radionuclide imaging

Indexed keywords

BREAST CANCER; CT SCAN; F-18 FDG PET/CT; FLARE PHENOMENON; LYMPH NODE METASTASIS; MEDICAL TREATMENT; POSITRON EMISSION; RADIONUCLIDE IMAGING;

CHEMOTHERAPY; POSITRONS; RADIOISOTOPES;

POSITRON EMISSION TOMOGRAPHY;

CYCLOPHOSPHAMIDE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; FLUORODEOXYGLUCOSE F 18; PROGESTERONE RECEPTOR; PROTEIN P53;

ADULT; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CASE REPORT; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DRUG UPTAKE; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MEDIASTINUM LYMPH NODE; MULTIPLE CYCLE TREATMENT; PARTIAL MASTECTOMY; PRIORITY JOURNAL; TUMOR FLARE;

ARTIFACTS; BREAST NEOPLASMS; FALSE POSITIVE REACTIONS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS;

EID: 70350169451     PISSN: 08997071     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinimag.2009.02.001     Document Type: Article

References (10)

1. Jansson T., Westlin J.E., Ahlstrom H., Lilja A., Langstrom B., and Bergh J. Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer: a method for early therapy evaluation?. J Clin Oncol 13 (1995) 1470-1477
2. 18F] FDG uptake in breast cancer during chemotherapy: comparison of analytical methods. Eur J Nucl Med Mol Imaging 30 (2003) 674-681
3. Zangheri B., Messa C., Picchio M., Gianolli L., Landoni C., and Fazio F. PET/CT and breast cancer. Eur J Nucl Med Mol Imaging 31 Suppl 1 (2004) S135-S142
4. Biersack H.J., Bender H., and Palmedo H. FDG-PET in monitoring therapy of breast cancer. Eur J Nucl Med Mol Imaging 31 Suppl 1 (2004) S112-S117
5. Hicks R.J. The role of PET in monitoring therapy. Cancer Imaging 5 (2005) 51-57
6. 18F]-fluorodeoxy-d-glucose to predict the pathologic response of breast cancer to primary chemotherapy. J Clin Oncol 18 (2000) 1676-1688
7. Mankoff D.A., Dunnwald L.K., Gralow J.R., Ellis G.K., Schubert E.K., Tseng J., et al. Changes in blood flow and metabolism in locally advanced breast cancer treated with neoadjuvant chemotherapy. J Nucl Med 44 (2003) 1806-1814
8. Dehdashti F., Flanagan F.L., Mortimer J.E., Katzenellenbogen J.A., Welch M.J., and Siegel B.A. Positron emission tomography assessment of "metabolic flare" to predict response of metastatic breast cancer to antiestrogen therapy. Eur J Nul Med 26 (1999) 51-56
9. 18F-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET study group. Eur J Cancer 35 13 (1999) 1773-1782
10. Basu S., and Alavi A. Defining co-related parameters between 'metabolic' flare and 'clinical', 'biochemical', and 'osteoblastic' flare and establishing guidelines for assessing response to treatment in cancer. Eur J Nucl Med Mol Imaging 34 (2007) 441-443